PM chairs Task Force meeting on Corona Vaccine Development, Drug Discovery, Diagnosis and Testing

In diagnosis and testing, several academic research institutions and start-ups have developed new tests, both for the RT-PCR approach and for antibody detection

Published On 2020-05-06 06:25 GMT   |   Update On 2020-05-06 06:25 GMT

New Delhi: The PM took a detailed review of the current status of India's efforts in vaccine development, drug discovery, diagnosis and testing. Indian vaccine companies are well known for their quality, manufacturing capacity and global presence. Today, in addition, they have come across as innovators in early-stage vaccine development research. Similarly, Indian academia and start-ups have...

Login or Register to read the full article

New Delhi: The PM took a detailed review of the current status of India's efforts in vaccine development, drug discovery, diagnosis and testing. Indian vaccine companies are well known for their quality, manufacturing capacity and global presence. Today, in addition, they have come across as innovators in early-stage vaccine development research. Similarly, Indian academia and start-ups have also pioneered in this area. Over 30 Indian vaccines are in different stages of corona vaccine development, with a few going on to the trial stages.

Similarly, in drug development, three approaches are being taken. First, the repurposing of existing drugs. At least four drugs are undergoing synthesis and examination in this category. Secondly, the development of new candidate drugs and molecules are being driven by linking high performance computational approached with laboratory verification. Thirdly, plant extracts and products are being examined for general anti-viral properties.

In diagnosis and testing, several academic research institutions and start-ups have developed new tests, both for the RT-PCR approach and for antibody detection. In addition, by linking laboratories all over the country, capacity for both these kinds of tests have been enormously scaled up. The problem of importing reagents for testing has been addressed by consortia of Indian start-ups and industry, meeting current requirements. The current thrust also holds promise for the development of a robust long-term industry in this area.

The review by the PM took note of the extraordinary coming together of academia, industry and government, combined with the speedy but efficient regulatory process. The PM desired that such coordination and speed should be embedded into a standard operating procedure. He emphasized that what is possible in a crisis should be a part of our routine way of scientific functioning.

Appreciating the scientific coming together of computer science, chemistry and biotechnology in drug discovery, the PM suggested that a hackathon be held on this subject, linking computer science to synthesis and testing in the laboratory. The successful candidates from the hackathon could be taken up by the start-ups for further development and scaling up.

The PM added that the innovative and original manner in which Indian scientists, from basic to applied sciences, have come together with industry is heartening. This kind of pride, originality and sense of purpose should dominate our approach going ahead. It is only then that we can be amongst the best in the world and not followers, in science.

Read also: Abbott gets CE Mark for COVID-19 laboratory-based antibody tests, to be available in India by May end


Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News